Venetoclax in Lymphoid Malignancies: New Insights, More to Learn

R Thijssen; AW Roberts

Journal article

Venetoclax in Lymphoid Malignancies: New Insights, More to Learn

R Thijssen, AW Roberts

Cancer Cell | CELL PRESS | Published : 2019

DOI: 10.1016/j.ccell.2019.09.008

Abstract

In this issue of Cancer Cell, Guièza et al. describe that overexpression of the pro-survival protein MCL1 and cellular energy metabolic reprogramming can contribute to resistance to the BCL2 inhibitor venetoclax in patients with chronic lymphocytic leukemia. This adds a new dimension to understanding of secondary clinical resistance to venetoclax.

University of Melbourne Researchers

Andrew Roberts Author

Related Projects (1)

TRANSLATING ADVANCES IN MOLECULAR ONCOLOGY INTO IMPROVED CARE FOR PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES

The purpose of my research is to develop and integrate into routine practice better treatment paradigms for patients with blood cancers – le..

Grants

Awarded by AbbVie

Funding Acknowledgements

R.T. is supported by a Fellowship for the Leukemia and Lymphoma Society (5467-18), and A.W.R is supported by a Practitioner Fellowship of the National Health and Medical Research Council of Australia (1079560).